NCT06680232RecruitingPhase 1
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- First submitted
- 24 Oct 2024
- Start date
- 14 Nov 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Precision BioSciences, Inc.
- Diseases
- Hepatitis B
- NCT number
- NCT06680232
- EU CT number
- 2025-524157-13-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 45
- From 14 Nov 2024 to the primary completion date, Dec 2026
- 7 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not received an organ transplant
- No investigational agent received within 6 months of screening
Other illness
- No history of cirrhosis of the liver
- No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant.
- No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer)
Other
- No signs of hepatocellular carcinoma
Who the study is looking for
- Male or women of non-child bearing potential
- BMI 18.0 to 35.0
- Good overall health deemed by the study Investigator
- CHB infection documented at least 12 months prior to screening
- HBeAg-negative CHB
- Must be virologically suppressed on current NA treatment
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Beaujon Coordinator of this site? Confirm its status | Clichy | France | Recruiting |
| Queen Mary Hospital, The University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
| ICS ARENSIA Exploratory Medicine SRL Coordinator of this site? Confirm its status | Chisinau | Moldova | Recruiting |
| New Zealand Clinical Research Coordinator of this site? Confirm its status | Auckland | New Zealand | Recruiting |
| National Institute of Infectious Diseases Prof. Dr. Matei Bal Coordinator of this site? Confirm its status | Bucharest | Romania | Recruiting |
| County Clinical Emergency Hospital Cluj-Napoca Coordinator of this site? Confirm its status | Cluj-Napoca | Romania | Recruiting |
| Massachusetts General Hospital-Harvard University Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.